We identified a novel human chondroitin N-acetylgalactosaminyltransferase, designated chondroitin GalNAcT-2 after a BLAST analysis of the GenBank database, using the sequence of a previously described human chondroitin Nacetylgalactosaminyltransferase (chondroitin GalNAcT-1) as a probe. The new cDNA sequence contained an open reading frame encoding a protein of 542 amino acids with a type II transmembrane protein topology. The amino acid sequence displayed 60% identity to that of human chondroitin GalNAcT-1. Like chondroitin GalNAcT-1, the expression of a soluble form of the protein in COS-1 cells produced an active enzyme, which not only transferred β1,4-N-acetylgalactosamine (GalNAc) from UDP-[ 3 H]GalNAc to a polymer chondroitin representing growing chondroitin chains (β-GalNAc transferase II activity), but also to GlcUAβ1-3Galβ1-O-C2H4NHCbz, a synthetic substrate for β-GalNAc transferase I that transfers the first GalNAc to the core tetrasaccharide in the protein-linkage region of chondroitin sulfate. In contrast, the tetrasaccharide-serine (GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser) derived from the linkage region, which is an inert acceptor substrate for chondroitin GalNAcT-1, served as an acceptor substrate. The coding region of this enzyme was divided into seven discrete exons, which is similar to the genomic organization of the chondroitin GalNAcT-1 gene, and was localized to chromosome 10q11.22. Northern blot analysis revealed that the chondroitin GalNAcT-2 gene exhibited a ubiquitous, but differing, expression in human tissues, and the expression pattern differed from that of chondroitin GalNAcT-1. Thus, we demonstrated redundancy in the chondroitin GalNAc transferases involved in the biosynthetic initiation and elongation of chondroitin sulfate, which is important for understanding the biosynthetic mechanisms leading to the selective chain assembly of chondroitin/dermatan sulfate on the linkage region tetrasaccharide common to various proteoglycans containing chondroitin/dermatan sulfate and heparin/heparan sulfate chains.
the glycosyltransferase gene family involved in chondroitin/dermatan sulfate biosynthesis, the chondroitin GalNAcT-1 protein sequence was used to screen a database. Here, we describe the cloning of a human cDNA encoding a novel chondroitin GalNAc transferase, designated chondroitin GalNAcT-2, that is similar to, but distinct from, chondroitin GalNAcT-1. 14 (Tokyo, Japan). Purified α-thrombomodulin (23) was provided by the research institute of Dai-ichi Pharmaceutical Co. (Tokyo, Japan), and contained the linkage tetrasaccharide GlcUAβ1-3Galβ1-3Galβ1-4Xyl (24) . The chemically synthesized linkage tetrasaccharide-serines GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser, GlcUAβ1-3Gal(4-O-sulfate)β1-3Galβ1-4Xylβ1-O-Ser, GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-(Gly)Ser-(Gly-Glu), and GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser-(Gly-Trp-ProAsp-Gly) were chemically synthesized (25, 26) . GlcUAβ1-3Galβ1-O-C2H4NHCbz was also synthesized (J. Tamura, unpublished results). Chondro-hexasaccharide (GlcUAβ1-3GalNAc) 3 was prepared from chondroitin, as previously described (27).
EXPERIMENTAL PROCEDURES

Materials-UDP-[U-
The Superdex TM Peptide HR10/30 column was obtained from Amersham Pharmacia Biotech (Uppsala, Sweden).
In Silico Cloning of the Novel Chondroitin GalNAcT cDNA-A tBLASTn
analysis of the GenBank TM database using the sequence of human chondroitin GalNAcT-1 (19) 
Expression of a Soluble Form of the Novel Chondroitin GalNAcT and
Enzyme Assays-The expression plasmid (6.7 µg) was transfected into COS-1 cells
(Gly)Ser-(Gly-Glu) (1 nmol), and GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser-(GlyTrp-Pro-Asp-Gly) (1 nmol), whereas that for GlcUA transferase was polymer chondroitin (167 µg). The assay mixture for GalNAcT contained 10 µl of the resuspended beads, an acceptor substrate, 8 Waters, Tokyo, Japan), as described previously (16, (30) (31) (32) (33) . The recovered labeled products were quantified by liquid scintillation spectrophotometry.
Identification of the Enzyme Reaction Products-The products of the
GalNAcT reaction using polymer chondroitin as the acceptor were isolated by gel filtration on a Superdex Peptide column equilibrated with 0.25 M NH 4 HCO 3 /7% 1-propanol. The radioactive fractions containing the enzyme reaction product were pooled and evaporated to dryness. The isolated GalNAcT reaction product (about 150 µg) was digested with 100 mIU of chondroitinase AC-II to assess digestibility in a total volume of 30 µl of 50 mM sodium acetate buffer, pH 6.0, at 37 ˚C overnight. The enzyme digest was analyzed using the Superdex Peptide column described above.
The products from the GalNAcT reaction using GlcUAβ1-3Galβ1-OC2H4NHCbz were isolated by HPLC on a Nova-Pak ® C18 column (described above)
in an LC-10A system (Shimadzu Co., Kyoto, Japan identity to human chondroitin GalNAcT-1 (Genbank TM accession No. AB071403) (Fig.   1 ); the highest sequence identity was found in the COOH-terminal domain, which has catalytic activity. Notably, each protein shared a conserved DVD motif ( Fig. 1 ), which appears to correspond to the conserved DXD motif found in most glycosyltransferases (36) . Therefore, the features of the identified protein sequence suggest that the 
Expression of a Soluble Form of the Novel Glycosyltransferase and its
Characterization as Chondroitin GalNAcT-2-To facilitate the functional analysis of the putative GalNAcT, a soluble form of the protein was generated by replacing the first The bound fusion protein was assayed for glycosyltransferase activity using a variety of acceptors and either UDP-GalNAc or UDP-GlcUA as a donor substrate. GlcUAβ1-3Galβ1-O-C2H4NHCbz, which was used as an acceptor substrate for the GalNAcT-I reaction, shares the disaccharide sequence with the GAG-protein linkage region tetrasaccharide. As shown in Table I , marked GalNAc transferase activity was detected with polymer chondroitin, chondro-hexasaccharide (GlcUAβ1-3GalNAc) 3 , α-thrombomodulin containing a linkage region tetrasaccharide, GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1, on the native core protein (24), GlcUAβ1-3Galβ1-O-C2H4NHCbz, the tetrasaccharide-serine, GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser, and the two tetrasaccharide-peptides, GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-(Gly)Ser-(Gly-Glu) and GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser-(Gly-Trp-Pro-Asp-Gly), but not with the sulfated tetrasaccharide-serine, GlcUAβ1-3Gal(4-O-sulfate)β1-3Galβ1-4Xylβ1-OSer, as acceptor substrates. In contrast, no GlcUA transferase activity was observed using polymer chondroitin. No detectable glycosyltransferase activity was recovered by affinity purification from a control pEF-BOS transfection sample. These findings clearly indicate that the expressed protein is a GalNAcT responsible for chondroitin biosynthesis.
To identify the GalNAcT reaction products, representative acceptor substrates, polymer chondroitin and GlcUAβ1-3Galβ1-O-C2H4NHCbz, were individually labeled via the respective transferase reaction using UDP- (Fig. 3A) or hydrophobic HPLC (Fig. 3B) . In contrast, both products were inert with respect to α-N-acetylgalactosaminidase, which is in marked contrast to the product of the α1,4-GalNAc transferase reaction catalyzed by EXTL2 (16). These findings indicate that a
GalNAc residue was indeed transferred to the nonreducing terminal GlcUA of the polymer chondroitin or GlcUAβ1-3Galβ1-O-C2H4NHCbz through a β1-4 linkage.
Combined, these results indicate that the identified protein is a novel β1,4-GalNAc transferase I/II involved in the initiation and elongation of chondroitin/dermatan sulfate.
Pattern of Chondroitin GalNAcT-2 Expression-Northern blot mRNA
analysis demonstrated a single ~3.9 kb band in all human tissues examined (Fig. 4) .
The gene exhibited a ubiquitous, but differing, expression in all the human tissues examined. Notably, the expression pattern differed from those of chondroitin
GalNAcT-1 and chondroitin synthase (Fig. 4) . The strongest signals were seen in the skeletal muscle, lung, and peripheral blood leukocytes. These findings are in accord with the observations that chondroitin/dermatan sulfate proteoglycans are distributed on the surfaces of most cells and in the extracellular matrices of virtually all tissue.
DISCUSSION
In this study, we identified a second human chondroitin GalNAcT, chondroitin
GalNAcT-2, which is homologous to, but distinct from, the previously cloned chondroitin GalNAcT-1. Chondroitin GalNAcT-2 is the fourth chondroitinsynthesizing glycosyltransferase cloned to date. As summarized in Table II Therefore, there are at least two types of enzymes involved in the synthesis of both chondroitin/dermatan sulfate and heparin/heparan sulfate: one for both chain initiation and elongation (chondroitin GalNAcT-1 and -2 and heparan sulfate GlcNAc transferase EXTL3, respectively) and the other for chain polymerization via the alternate transfer of GlcUA and GalNAc or GlcNAc (chondroitin synthase and heparan sulfate copolymerases EXT1 and EXT2, respectively). Intriguingly, these combined findings suggest that the assembly of the polysaccharide backbones of chondroitin sulfate and heparan sulfate shares a similar biosynthetic mechanism irrespective of the involvement of the two distinct glycosyltransferase gene families.
As shown in Table I , the two recombinant chondroitin GalNAcTs exhibited both GalNAcT-I and -II activities, and polymer chondroitin was the best substrate for both enzymes. However, chondroitin GalNAcT-2 showed broader acceptor specificity than chondroitin GalNAcT-1, as the former utilized all of the acceptor substrates tested that contained terminal β1,3-linked GlcUA residues, except for the sulfated tetrasaccharide-serine, GlcUAβ1-3Gal(4-O-sulfate)β1-3Galβ1-4Xylβ1-O-Ser (Table I) .
Notably, no such chondroitin GalNAcT has been reported. Chondroitin GalNAcT-2 is a unique β1,4-GalNAc transferase that utilizes the tetrasaccharide-serine, GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser, from the linkage region as an acceptor substrate.
Previously, when this compound was tested as an acceptor together with a sugar donor, UDP-GalNAc, to search for such GalNAcTs using fetal bovine sera or mouse mastocytoma cell extracts as the enzyme source, only α-GalNAc transferase activity was detected, resulting in the exclusive production of an α-GalNAc-capped pentasaccharide, GalNAcα1-4GlcUAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser (27, 40, 41).
Therefore, high expression of α-GalNAc transferase might have interfered with the identification of a β1,4-GalNAc transferase, such as chondroitin GalNAcT-2.
Chondroitin GalNAcT-2, like chondroitin GalNAcT-1, transfers the first β1,4- Interestingly, the chondroitin GalNAcT-2 activity was inhibited when the sulfated tetrasaccharide-serine was used as an acceptor (Table I ). The 4-O-sulfated Gal residue has been identified in the linkage region of chondroitin/dermatan sulfate, but not in that of heparin/heparan sulfate (46, 47). Hence, it is hypothesized that it is recognized by a chondroitin GalNAcT specific for the linkage region and might be a molecular signal that promotes chondroitin chain synthesis segregating it from heparan chain (9).
However, the negative results obtained in this study do not appear to support this possibility, although its function remains unclear.
In addition, the respective roles of the GalNAcT-II activity of chondroitin
GalNAcT-1 and -2 in the chain polymerization of chondroitin/dermatan sulfate remain to be clarified, especially where it requires GlcAT-II as a partner. It is not known whether chondroitin synthase or chondroitin GlcUA transferase co-operates with chondroitin GalNAcT-1 and/or -2 to synthesize the repeating disaccharide region or in chain polymerization, or whether an as yet unidentified GlcAT-II with no homology to the known genes exists in addition to chondroitin synthase and chondroitin GlcUA transferase. A multimeric complex might also exist. In this context, no chondroitin chain polymerizing enzyme activity has been demonstrated in vitro for chondroitin synthase (18) . If either chondroitin GalNAcT-1 or -2 is associated with chondroitin synthase, chondroitin/dermatan sulfate chains might possibly be initiated and polymerized efficiently on the tetrasaccharide core. However, such hetero-oligomeric complex formation has not been reported, and is the subject of a future study.
The chondroitin GalNAcT-1 and -2 genes exhibit unique tissue-specific patterns of expression. Particularly striking is the abundant expression of the chondroitin GalNAcT-2 gene in the skeletal muscle, lung, and peripheral blood leukocytes, with modest expression in the brain, thymus, and placenta (Fig. 4) . In contrast, chondroitin
GalNAcT-1 is abundantly expressed in the placenta, followed by the heart and small intestine, and very little is expressed in colon and thymus (19) , similar to the pattern of chondroitin synthase expression (18) . Therefore, chondroitin GalNAcT-2 may play a unique role in the biosynthesis of chondroitin sulfate in certain tissues in view of the different specificities (Table I ) and distinct tissue expression of chondroitin GalNAcT-1 and -2 (Fig. 4) . The production and analysis of chondroitin GalNAcT-1 or -2 knockout mice would provide further insights into the possible distinct functions of these genes.
The genomic organization of the four cloned chondroitin glycosyltransferases involved in chondroitin backbone formation has been elucidated. The protein-coding sequences of the human chondroitin GalNAcT-1 and -2 genes are distributed among seven exons that span approximately 120 (19) and 30 kb (this study), respectively.
Comparison of the genomic organizations of these two genes shows a quite similar genetic exon-intron organization within the coding sequences (Fig. 2) . In contrast, the (Table II) , respectively, despite the significant homology in the nucleotide and amino acid sequences of the four genes. These findings suggest that the four chondroitin glycosyltransferases diverged from an ancestor gene early in evolution.
As described previously (18, 19) , a homologue of human chondroitin synthase is present in C. elegans and Drosophila, which is consistent with the finding of chondroitin and chondroitin 4-sulfate in C. elegans and Drosophila, respectively (48) (49) (50) . Notably, however, a homologue of human chondroitin GalNAcT-1 or -2 is absent from C. elegans, but is present in 'higher' species, such as Drosophila (Fig. 1) . It is possible that the biosynthetic mechanism for chondroitin sulfate in C. elegans is similar to, but different from, that in mammals, although the conventional linkage region tetrasaccharide sequence has recently been identified not only in Drosophila but also in C. elegans (51) .
The mechanism for the selective chain assembly of chondroitin/dermatan sulfate and heparin/heparan sulfate on the common linkage region tetrasaccharide has been an enigma since the discovery of the common linkage region tetrasaccharide in the mid 1960s (7, 9) . cDNA probes for enzymes harboring GalNAcT-I or GlcNAc transferase I activity (15, 16, 19) , are now available for investigating the biological functions of chondroitin/dermatan sulfate, as well as the mechanism of selective chain assembly of chondroitin/dermatan sulfate and heparin/heparan sulfate.
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